by Instem Team | Apr 8, 2026 | In Silico & Data Insights, Regulatory Submission, Study Management
CMC Readiness CMC (Chemistry, Manufacturing and Controls) readiness is a major hurdle during drug discovery and development. Sufficient, compliant data and documentation regarding the manufacturing process, product stability, and quality controls of a drug are...
by Instem Team | Apr 1, 2026 | In Silico & Data Insights, Regulatory Submission, Study Management
Toxicology Preclinical safety is a crucial aspect of drug discovery. The goal at this stage is to conduct and assess toxicology, safety pharmacology, genetic toxicology, and reproductive toxicology11. Histopathology, clinical chemistry, cardiovascular, and genetic...
by Instem Team | Mar 31, 2026 | Quality System Management, Study Management
Life science organizations must maintain rigorous data integrity and compliance while operating across expanding, often global, environments. Yet many still rely on fragmented document repositories, manual workflows, and disconnected training systems, structures that...
by Instem Team | Mar 26, 2026 | Clinical
Open-source software has transformed how life sciences organizations approach analytics. Tools such as R offer flexibility, rapid innovation, and a rich diversity of community-developed packages. However, open-source adoption in regulated clinical environments comes...
by Instem Team | Mar 25, 2026 | In Silico & Data Insights, Regulatory Submission, Study Management
Preclinical Efficacy Preclinical efficacy studies serve as a key bridge between discovery and the later stages of drug development. These studies examine the mechanism of action and efficacy of lead compounds against disease models. This is a pivotal translation...
